Division of Gastroenterology, University of California, San Diego School of Medicine, La Jolla, California, USA.
Division of Gastroenterology, Washington University School of Medicine, St. Louis, Missouri, USA.
Am J Gastroenterol. 2022 Oct 1;117(10):1573-1582. doi: 10.14309/ajg.0000000000001871. Epub 2022 Jun 10.
INTRODUCTION: Ambulatory reflux monitoring performed off proton pump inhibitor (PPI) is the gold standard diagnostic test for nonerosive gastroesophageal reflux disease (GERD). However, the diagnostic metrics and optimal duration of monitoring are not well defined. This study evaluated the performance of multiple metrics across distinct durations of wireless reflux monitoring off PPI against the ability to discontinue PPI therapy in patients with suboptimal PPI response. METHODS: This single-arm clinical trial performed over 4 years at 2 centers enrolled adults with troublesome GERD symptoms and inadequate response to > 8 weeks of PPI. Participants underwent 96-hour wireless pH monitoring off PPI. Primary outcome was whether the subject successfully discontinued PPI or resumed PPI within 3 weeks. RESULTS: Of 132 participants, 30% discontinued PPI. Among multiple metrics assessed, total acid exposure time (AET) of 4.0% performed best in predicting PPI discontinuation (odds ratio 2.9 [95% confidence interval 1.4, 6.4]; P = 0.006), with other thresholds of AET and DeMeester score performing comparably. AET was significantly higher on day 1 of monitoring compared with other days, and prognostic performance significantly declined when only assessing the first 48 hours of monitoring (area under the curve for 96 hours 0.63 vs area under the curve for 48 hours 0.57; P = 0.01). DISCUSSION: This clinical trial highlights the AET threshold of 4.0% as a high-performing prognostic marker of PPI discontinuation. 96 hours of monitoring performed better than 48 hours, in predicting ability to discontinue PPI. These data can inform current diagnostic approaches for patients with GERD symptoms who are unresponsive to PPI therapy.
简介:在停用质子泵抑制剂 (PPI) 后进行的门诊反流监测是诊断非糜烂性胃食管反流病 (GERD) 的金标准诊断测试。然而,诊断指标和监测的最佳持续时间尚不清楚。本研究评估了在对 PPI 反应不佳的患者中,使用 PPI 停药后不同时间无线反流监测的多个指标与停止 PPI 治疗能力之间的关系。
方法:这项为期 4 年在 2 个中心进行的单臂临床试验纳入了有 GERD 症状且对 >8 周 PPI 治疗反应不佳的成年人。参与者接受了 96 小时无线 pH 监测,停用 PPI。主要结局是受试者是否成功停用 PPI 或在 3 周内恢复 PPI。
结果:在 132 名参与者中,有 30%的患者停用了 PPI。在评估的多个指标中,总酸暴露时间(AET)为 4.0%,在预测 PPI 停药方面表现最佳(优势比 2.9[95%置信区间 1.4,6.4];P=0.006),其他 AET 和 DeMeester 评分的阈值表现相当。与其他天数相比,监测的第 1 天 AET 显著更高,仅评估前 48 小时监测的预后性能显著下降(96 小时的曲线下面积为 0.63,48 小时的曲线下面积为 0.57;P=0.01)。
讨论:本临床试验强调 AET 阈值为 4.0%是预测 PPI 停药的高表现预后标志物。与 48 小时相比,96 小时的监测能更好地预测 PPI 停药的能力。这些数据可以为对 PPI 治疗无反应的 GERD 症状患者的当前诊断方法提供信息。
Am J Gastroenterol. 2022-10-1
Neurogastroenterol Motil. 2013-8-29
United European Gastroenterol J. 2019-10-9
Aliment Pharmacol Ther. 2022-10
Aliment Pharmacol Ther. 2022-6
Clin Gastroenterol Hepatol. 2020-12
Clin Gastroenterol Hepatol. 2012-7-17
Gastrointest Endosc Clin N Am. 2025-7
Clin Gastroenterol Hepatol. 2025-5-16
Am J Gastroenterol. 2025-4-8
Curr Treat Options Gastroenterol. 2025-12
Aliment Pharmacol Ther. 2024-3
Am J Gastroenterol. 2024-4-1
Clin Gastroenterol Hepatol. 2024-10